PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9626925-4	1998	RESULTS: From the experiments using ten expressed human CYPs, CYP2C19, CYP3A4 and CYP3A5 were shown to be capable of catalyzing zonisamide reduction.	Zonisamide	128-138	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	71-77	
9626925-6	1998	From the point of view of enzyme amount in human liver CYPs isoform and their intrinsic clearance, it was suggested that CYP3A4 is mainly responsible for zonisamide metabolism in human CYPs.	Zonisamide	154-164	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	121-127	
9626925-12	1998	CONCLUSION: We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide.	Zonisamide	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85	
9626925-12	1998	CONCLUSION: We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide.	Zonisamide	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-175	
9626925-12	1998	CONCLUSION: We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide.	Zonisamide	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-175	
9626925-12	1998	CONCLUSION: We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide.	Zonisamide	392-402	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-175	
9626925-12	1998	CONCLUSION: We demonstrated that: (1) zonisamide is metabolized by recombinant CYP3A4, CYP2C19 and CYP3A5, (2) the metabolism is inhibited to a variable extent by known CYP3A4/5 substrates and/or inhibitors in human liver microsomes, and (3) in vitro-in vivo predictive calculations suggest that several compounds demonstrating CYP3A4-affinity might cause in vivo drug-drug interactions with zonisamide.	Zonisamide	392-402	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	169-175	
20205992-4	2010	Zonisamide is well absorbed with maximum concentration achieved in 2 to 5 h. It is partly metabolized by the CYP3A4.	Zonisamide	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	109-115	
15519127-8	2004	The estimated Ki for zonisamide inhibition of CYP3A4 was 1076 microM, 12 times higher than typical unbound therapeutic serum zonisamide concentrations.	Zonisamide	21-31	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	46-52	
15519127-11	2004	The observed mean zonisamide t1/2 (36.3h), relative to approximately 65 h reported in subjects on zonisamide monotherapy, reflects known CYP3A4 induction by carbamazepine.	Zonisamide	18-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143	
17553670-5	2007	Zonisamide has no clinically relevant effects on the pharmacokinetics of other commonly used AEDs, however, co-administration with cytochrome P450 3A4 (CYP3A4) inducers or inhibitors may change zonisamide"s pharmacokinetic profile.	Zonisamide	194-204	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-150	
17553670-5	2007	Zonisamide has no clinically relevant effects on the pharmacokinetics of other commonly used AEDs, however, co-administration with cytochrome P450 3A4 (CYP3A4) inducers or inhibitors may change zonisamide"s pharmacokinetic profile.	Zonisamide	194-204	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158